These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 28677314)

  • 1. Improvement in renal function and resolution of proteinuria in an HIV-infected patient switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
    Gallagher A; Quan D; Gracey DM
    Intern Med J; 2017 Jul; 47(7):826-827. PubMed ID: 28677314
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial.
    Gallant JE; Daar ES; Raffi F; Brinson C; Ruane P; DeJesus E; Johnson M; Clumeck N; Osiyemi O; Ward D; Morales-Ramirez J; Yan M; Abram ME; Plummer A; Cheng AK; Rhee MS
    Lancet HIV; 2016 Apr; 3(4):e158-65. PubMed ID: 27036991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study.
    Lampertico P; Buti M; Fung S; Ahn SH; Chuang WL; Tak WY; Ramji A; Chen CY; Tam E; Bae H; Ma X; Flaherty JF; Gaggar A; Lau A; Liu Y; Wu G; Suri V; Tan SK; Subramanian GM; Trinh H; Yoon SK; Agarwal K; Lim YS; Chan HLY
    Lancet Gastroenterol Hepatol; 2020 May; 5(5):441-453. PubMed ID: 32087795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is Tenofovir Alafenamide Safer than Tenofovir Disoproxil Fumarate for the Kidneys?
    Aloy B; Tazi I; Bagnis CI; Gauthier M; Janus N; Launay-Vacher V; Deray G; Tourret J
    AIDS Rev; 2016; 18(4):184-192. PubMed ID: 27438578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal function change after switching tenofovir disoproxil fumarate for tenofovir alafenamide in the HIV-positive patients of a metropolitan sexual health service.
    Turner D; Drak D; O'Connor CC; Templeton DJ; Gracey DM
    AIDS Res Ther; 2019 Dec; 16(1):40. PubMed ID: 31810490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short Communication: Resolution of Tenofovir Disoproxil Fumarate Induced Fanconi Syndrome with Switch to Tenofovir Alafenamide Fumarate in a HIV-1 and Hepatitis B Coinfected Patient.
    Karris MY
    AIDS Res Hum Retroviruses; 2017 Jul; 33(7):718-722. PubMed ID: 28403627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
    Orkin C; DeJesus E; Ramgopal M; Crofoot G; Ruane P; LaMarca A; Mills A; Vandercam B; de Wet J; Rockstroh J; Lazzarin A; Rijnders B; Podzamczer D; Thalme A; Stoeckle M; Porter D; Liu HC; Cheng A; Quirk E; SenGupta D; Cao H
    Lancet HIV; 2017 May; 4(5):e195-e204. PubMed ID: 28259777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
    DeJesus E; Ramgopal M; Crofoot G; Ruane P; LaMarca A; Mills A; Martorell CT; de Wet J; Stellbrink HJ; Molina JM; Post FA; Valero IP; Porter D; Liu Y; Cheng A; Quirk E; SenGupta D; Cao H
    Lancet HIV; 2017 May; 4(5):e205-e213. PubMed ID: 28259776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide: perhaps not as simple as we thought.
    Mak LY
    Lancet Gastroenterol Hepatol; 2020 May; 5(5):420-421. PubMed ID: 32087794
    [No Abstract]   [Full Text] [Related]  

  • 10. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    Chan HL; Fung S; Seto WK; Chuang WL; Chen CY; Kim HJ; Hui AJ; Janssen HL; Chowdhury A; Tsang TY; Mehta R; Gane E; Flaherty JF; Massetto B; Gaggar A; Kitrinos KM; Lin L; Subramanian GM; McHutchison JG; Lim YS; Acharya SK; Agarwal K;
    Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):185-195. PubMed ID: 28404091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early safety of tenofovir alafenamide in patients with a history of tubulopathy on tenofovir disoproxil fumarate: a randomized controlled clinical trial.
    Hamzah L; Williams D; Bailey AC; Jones R; Ibrahim F; Musso CG; Burling K; Barbini B; Campbell L; Post FA;
    HIV Med; 2020 Mar; 21(3):198-203. PubMed ID: 31679186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection.
    Agarwal K; Fung SK; Nguyen TT; Cheng W; Sicard E; Ryder SD; Flaherty JF; Lawson E; Zhao S; Subramanian GM; McHutchison JG; Gane EJ; Foster GR
    J Hepatol; 2015 Mar; 62(3):533-40. PubMed ID: 25450717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    Buti M; Gane E; Seto WK; Chan HL; Chuang WL; Stepanova T; Hui AJ; Lim YS; Mehta R; Janssen HL; Acharya SK; Flaherty JF; Massetto B; Cathcart AL; Kim K; Gaggar A; Subramanian GM; McHutchison JG; Pan CQ; Brunetto M; Izumi N; Marcellin P;
    Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):196-206. PubMed ID: 28404092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching tenofovir disoproxil fumarate to tenofovir alafenamide results in a significant decline in parathyroid hormone levels: uncovering the mechanism of tenofovir disoproxil fumarate-related bone loss?
    Van Welzen BJ; Thielen MAJ; Mudrikova T; Arends JE; Hoepelman AIM
    AIDS; 2019 Jul; 33(9):1531-1534. PubMed ID: 31021851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults.
    Markowitz M; Zolopa A; Squires K; Ruane P; Coakley D; Kearney B; Zhong L; Wulfsohn M; Miller MD; Lee WA
    J Antimicrob Chemother; 2014 May; 69(5):1362-9. PubMed ID: 24508897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenofovir alafenamide as part of a salvage regimen in a patient with multi-drug resistant HIV and tenofovir-DF-associated renal tubulopathy.
    Mikula JM; Manion MM; Maldarelli F; Suarez LM; Norman-Wheeler JF; Ober AG; Dewar RL; Kopp JB; Lane HC; Pau AK
    Antivir Ther; 2016; 21(6):553-558. PubMed ID: 26954372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF).
    De Clercq E
    Biochem Pharmacol; 2016 Nov; 119():1-7. PubMed ID: 27133890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenofovir alafenamide nephrotoxicity in an HIV-positive patient: A case report.
    Novick TK; Choi MJ; Rosenberg AZ; McMahon BA; Fine D; Atta MG
    Medicine (Baltimore); 2017 Sep; 96(36):e8046. PubMed ID: 28885375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translation of clinical trial data to changes in clinical practice: rapid transition from tenofovir disoproxil fumarate to tenofovir alafenamide-based therapies in a Sydney HIV clinic.
    Smith DE; Tom M; Bowden BH
    Int J STD AIDS; 2018 Sep; 29(10):1011-1013. PubMed ID: 29621950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
    Fong TL; Lee BT; Tien A; Chang M; Lim C; Ahn A; Bae HS
    J Viral Hepat; 2019 May; 26(5):561-567. PubMed ID: 30576085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.